YES Study - Newly Diagnosed/Metastatic Intervention
Launched by DANA-FARBER CANCER INSTITUTE · May 5, 2020
Trial Information
Current as of July 01, 2025
Recruiting
Keywords
ClinConnect Summary
The YES Study is a research project designed to support young women aged 18-39 who have recently been diagnosed with breast cancer, whether it's early-stage (stage 0-3) or advanced (stage IV). The study focuses on understanding common symptoms and behaviors associated with breast cancer, while also providing helpful information about care and connecting participants with peers who are going through similar experiences. This is done through a user-friendly online platform that can be accessed on smartphones, tablets, and computers.
To participate in the study, you need to be a female diagnosed with breast cancer within the last three months and have not started any treatment yet. You should also plan to receive care at the Dana-Farber Cancer Institute (DFCI), be fluent in English, and have regular internet access. If you join the study, you can expect to share your experiences and receive support, which can be very beneficial during this challenging time.
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • Stage 0-3
- • Female
- • diagnosed with breast cancer between the ages of 18-39 years
- • less than 3 months post diagnosis date of new primary or local recurrence (prior history of other cancer is allowed as long as treated with curative intent and no evidence of disease from that cancer)
- • has not started treatment for breast cancer diagnosis yet
- • is planning to get care at DFCI
- • be fluent in and able to read English
- • have internet access on a regular basis at the time of consent that can support the web-based platform
- • Stage IV
- • Female
- • initial diagnosis of breast cancer between the ages of 18-39 years
- • be fluent in and able to read English
- • have internet access on a regular basis at the time of consent that can support the web-based platform
- Exclusion Criteria:
- • -
About Dana Farber Cancer Institute
The Dana-Farber Cancer Institute is a premier cancer research and treatment institution located in Boston, Massachusetts. Renowned for its commitment to advancing cancer care through innovative research, the institute integrates cutting-edge clinical trials with a multidisciplinary approach to patient care. With a focus on translating scientific discoveries into effective therapies, Dana-Farber collaborates with a network of leading researchers and healthcare professionals to improve outcomes for patients with cancer. The institute’s dedication to education, advocacy, and community engagement further underscores its mission to eradicate cancer and enhance the quality of life for those affected by the disease.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Boston, Massachusetts, United States
Patients applied
Trial Officials
Ann H Partridge, MD
Principal Investigator
Dana-Farber Cancer Institute
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials